)
Visual
earnings real time
CV Sciences
CV Sciences (CVSI) investor relations material
CV Sciences Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary13 Nov, 2025
Executive summary
Q3 2025 revenue was $3.3 million, down 16% year-over-year and 10% sequentially, mainly due to out-of-stock issues and restrictive regulation in some states.
Gross margin improved to 48.5% from 46% a year ago, reflecting strong cost control and improved product/channel mix.
Adjusted EBITDA loss was $118,000, compared to a $75,000 loss last year and a $59,000 profit in Q2.
Net loss for Q3 2025 was $0.4 million, improved from $0.5 million last year.
39% of Q3 2025 revenue came from products launched since January 2023, with 38 new products introduced.
Financial highlights
Q3 2025 net product sales: $3.3 million (down from $3.9 million in Q3 2024); gross margin: 48.5% (up from 46.0%).
SG&A expenses for Q3 2025 decreased to $1.8 million from $2.1 million year-over-year.
Net loss per share for Q3 2025 remained at $0.00.
Cash at quarter-end was $0.4 million, down from $0.5 million at year-end.
Cash used in operations for the nine months ended September 30, 2025 was $1.08 million.
Outlook and guidance
Management expects continued dependence on additional investment capital to fund operations and growth initiatives.
Strategic cost reductions, product innovation, and acquisition integration are ongoing to improve competitiveness and drive future growth.
New federal legislation effective November 2026 will prohibit sale of hemp-derived products with >0.4mg THC per container, potentially impacting future product offerings and revenue.
Full cost savings from insourcing manufacturing and acquisition synergies expected in 2026.
Plans to launch several new cannabinoid and non-cannabinoid products in early 2026.
Product strategy for 0.4mg THC limit
Expected 2026 cost savings from in-sourcing?
How to reverse Q3 revenue decline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- VSH
Q4 2025 revenue up 12% YoY to $800.9M, with strong orders and growth outlook for Q1 2026. - 6752
Profit and sales fell on restructuring, but adjusted OP rose on strong Connect, Industry, and Energy. - CTSH
Revenue and EPS grew 7% and 11% in 2025, with strong 2026 growth outlook. - CTVA
2025 saw record EBITDA and cash flow, with 2026 set for further growth and separation benefits. - SAP
Earnings and profitability declined sharply amid weak markets, cost pressures, and higher leverage. - EFX
2026 guidance targets 10.6% revenue growth, 11% EPS growth, and over $1B free cash flow. - BDN
2026 targets FFO growth, higher occupancy, major asset sales, and further deleveraging. - GEHC
Strong 2025 results, record backlog, and 2026 growth guided at 3%-4% with margin expansion. - SANB4
Q4 2025 net profit was BRL 4.1B, ROE 17.6%, with strong digital and SME-driven growth. - SNP
Q4 2025 delivered robust Clean CCS and cash flow, but net income was hit by E&P impairments.
Next CV Sciences earnings date
Q4 202527 Mar, 2026
CV Sciences
Next CV Sciences earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
CV Sciences Inc. is a life sciences company focused on developing and commercializing products derived from hemp-based cannabidiol (CBD). The company's offerings include consumer health products, such as dietary supplements and topical formulations, that promote wellness and support various health needs. CV Sciences operates through two primary segments: consumer products and drug development. The consumer products division produces CBD-based products under the PlusCBD brand, while the drug development segment is involved in researching CBD-based therapeutics. The company is headquartered in San Diego, California, and its shares are listed on the OTCQB.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage